91Â鶹ÌìÃÀÖ±²¥

Journal Article

1. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K (2023). Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(5), 503-513. ()
2. Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, Wang ES, Shami PJ, Adekola K, Luger S, Baer MR, Rizzieri DA, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Schuler TA, Leisenring WM, Onstad LE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey EH (2022). An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML. Blood, 141(3), 295-308. ()
3. Shami PJ (2023). Development of JS-K, a First-in-Class Arylated Diazeniumdiolate, for the Treatment of Cancer. Crit Rev Oncog, 28(1), 57-62. ()
4. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C (2022). NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw, 20(2), 106-117. ()
5. Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ, Cull E, Lee C, Cogle CR, Lin TL (2021). Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers (Basel), 13(21). ()
6. Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, Shami PJ, Cull E, Cogle CR, Watts J (2021). A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers (Basel), 13(16). ()
7. Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Pea E, Elsawy M, Adekola K, Luger S, Baer MR, Rizzieri D, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring W, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey EH (2020). Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 138(5), 387-400. ()
8. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510. ()
9. Sorror ML, Storer BE, Fathi AT, Brunner AM, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Pea E, Elsawy M, Adekola KUA, Luger S, Baer MR, Rizzieri D, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring WM, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum F, Estey EH (2021). Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood. ()
10. Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS (2021). NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw, 19(1), 16-27. ()
11. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991. ()
12. Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, Lin TL, Nand S, Pierce KJ, Shami PJ, Vermette JJ, Abboud CN (2020). Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma, 61(8), 1965-1973. ()
13. Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem D (2019). Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leuk Res, 87, 106262. ()
14. Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, Rasmussen E, Henary HA, Anderson AA, Wang ES (2019). Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood Adv, 3(13), 1939-1949. ()
15. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, ODonnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, OCN, Hammond L, Ogba N (2019). Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17(6), 721-749. ()
16. Wang J, Li L, Yang J, Clair PM, Glenn MJ, Stephens DM, Radford DC, Kosak KM, Deininger MW, Shami PJ, Kopeek J (2019). Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. Nanomedicine, 16, 217-225. ()
17. Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Pea E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH (2017). Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol, 3(12), 1675-1682. ()
18. Zhang R, Yang J, Zhou Y, Shami PJ, Kopeek J (2016). N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia. Macromol Biosci, 16(1), 121-8. ()
19. Rudrapatna VK, Morley K, Boucher KM, Pierson AS, Shull CT, Kushner JP, Shami PJ (2015). Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. Leuk Res, 39(8), 835-9. ()
20. Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kopeek J (2015). A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics, 5(8), 834-46. ()
21. Kaur I, Kosak KM, Terrazas M, Herron JN, Kern SE, Boucher KM, Shami PJ (2015). Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K. Pharm Res, 32(4), 1395-406. ()
22. Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, ODonnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C, National comprehensive cancer network (2015). Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw, 13(3), 261-72. ()
23. Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F (2015). REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol, 168(6), 796-805. ()
24. Chu TW, Kosak KM, Shami PJ, Kopeek J (2014). Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells. Drug Deliv Transl Res, 4(5-6), 389-94. ()
25. Zhuo R, Kosak KM, Sankar S, Wiles ET, Sun Y, Zhang J, Ayello J, Prestwich GD, Shami PJ, Cairo MS, Lessnick SL, Luo W (2014). Targeting Glutathione S-transferase M4 in Ewing sarcoma. Front Pediatr, 2, 83. ()
26. Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI (2014). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. J Natl Compr Canc Netw, 12(8), 1113-21. ()
27. ODonnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M, National Comprehensive Cancer Network (2013). Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw, 11(9), 1047-55. ()
28. Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami PJ (2013). Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles. J Pharm Pharmacol, 65(9), 1329-36. ()
29. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, ODonnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M (2013). Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw, 11(7), 838-74. ()
30. Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock A (2013). Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric Oxide, 30, 17-25. ()
31. Slomowitz SJ, Shami PJ (2012). Management of extramedullary leukemia as a presentation of acute myeloid leukemia. J Natl Compr Canc Netw, 10(9), 1165-9. ()
32. ODonnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM (2012). NCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Netw, 10(8), 984-1021. ()
33. Nandurdikar RS, Maciag AE, Holland RJ, Cao Z, Shami PJ, Anderson LM, Keefer LK, Saavedra JE (2012). Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs. Bioorg Med Chem, 20(9), 3094-9. ()
34. Shami PJ (2012). How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients. J Natl Compr Canc Netw, 10(1), 112-8; quiz 119. ()
35. OBrien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VV, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F, National Comprehensive Cancer Network (2012). Chronic myelogenous leukemia. J Natl Compr Canc Netw, 10(1), 64-110. ()
36. Maciag AE, Holland RJ, Saavedra JE, Chakrapani H, Shami PJ, Keefer LK (2012). Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class. For Immunopathol Dis Therap, 3(2), 91-95. ()
37. Narayanan S, Shami PJ (2012). Treatment of acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol, 81(1), 94-102. ()
38. Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE (2011). Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs. J Med Chem, 54(22), 7751-8. ()
39. ODonnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, National Comprehensive Cancer Network (2011). Acute myeloid leukemia. J Natl Compr Canc Netw, 9(3), 280-317. ()
40. Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK (2011). The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species. J Pharmacol Exp Ther, 336(2), 313-20. ()
41. OBrien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler M (2011). NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw, 9 Suppl 2, S1-25. ()
42. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, ODonnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer Network (2011). NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw, 9(1), 30-56. ()
43. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S (2010). Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol, 28(4), 549-55. ()
44. Edes K, Cassidy P, Shami PJ, Moos PJ (2010). JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1. PLoS One, 5(1), e8786. ()
45. Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ (2010). JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol, 62(1), 145-51. ()
46. Kiziltepe T, Anderson KC, Kutock JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ (2010). JS-K has Potent Anti-Angiogenic Activity In Vitro and Inhibits Tumor Angiogenesis in a Multiple Myeloma Model In Vivo. J Pharm Pharmacol, 62, 145-151.
47. Kantarjian HM, Erba HP, Claxton D, Arellano M, Craig M, Douer D, Gabrilove J, Lyons R, Kovascovics T, Maris M, Petersdorf S, Shami PJ, Yaeger A, Eckert S, Abichandani R, Faderl S, On behalf of the CLASSIC II Investigators (2010). Phase II Study of Clofarabine Induction and Consolidation Therapy In Previously Untreated Older Adults With Acute Myelogenous Leukemia for Whom Conventional Induction Chemotherapy is Unlikely to be of Benefit Due to Unfavorable Baseline Risk Factors. J Clin Oncol, 28, 549-555.
48. Shami PJ, Maciag AE, Eddington JK, Udupi V, Kosak KM, Saavedra JE, Keefer LK (2009). JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leuk Res, 33(11), 1525-9. ()
49. OBrien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M, National Comprehensive Cancer Network (2009). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw, 7(9), 984-1023. ()
50. Liu J, Malavya S, Wang X, Saavedra JE, Keefer LK, Tokar E, Qu W, Waalkes MP, Shami PJ (2009). Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells. Genomics, 94(1), 32-8. ()
51. Saade M, Salamoun W, Tueni E, Shami PJ (2000). Who should be screened for hereditary breast cancer and what should be done with the information? J Med Liban, 47(5), 281-3. ()
52. Shami PJ, Crews J (1995). Megaloblastic cytopenia in an AIDS patient treated with trimethoprim-sulfamethoxazole. N C Med J, 56(12), 602-4. ()
53. Ciaccia D, Quigley RL, Shami PJ, Grant JP (1994). A case of retrograde jejunoduodenal intussusception caused by a feeding gastrostomy tube. Nutr Clin Pract, 9(1), 18-21. ()

Review

1. Shami PJ, Deininger M (2012). Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. [Review]. Leukemia, 26(2), 214-24. ()
2. Zeng J, Yang N, Li XM, Shami PJ, Zhan J (2010). 4'-O-Methylglycosylation of Curcumin by Beauveria bassiana. [Review]. Nat Prod Commun, 5, 77-80.

Abstract

1. Rudrapatna RK, Morley K, Kushner JP, Pierson AS, Shull CT, Shami PJ (2013). Phase I Trial of Low-Dose Oral Clofarabine in Myelodysplastic Syndromes Patients Who Have Failed Frontline Therapy [Abstract]. Proceedings of the 2013 meeting of the American Association for Cancer Research.
2. Rudrapatna R, Kosak KM, Terrazas M, Kennedy TP, Shami PJ (2010). Development of Dithiocarbamate/Metal Complexes in Pluronic® micelles for the Treatment of Malignancies [Abstract]. Proceedings of the 2010 meeting of the American Association for Cancer Research, 5526.
3. Kaur I, Kosak KM, Saavedra JE, Keefer LK, Kern Se, Shami PJ (2010). Cellular uptake and stability studies of the nitric oxide-generating pro-drug JS-K [Abstract]. Proceedings of the 2010 meeting of the American Association for Cancer Research, 2651.
4. Maciag AE, Chakrapani H, Holland RJ, Morris JL, Shami PJ, Saavedra JE, Anderson LM, Keefer LK (2010). Diazeniumdiolate-based nitric oxide-releasing prodrugs kill lung adenocarcinoma in cells in culture and in vivo through alterations in cellular redox balance leading to mitochondrially-mediated apoptosis [Abstract]. Proceedings of the 2010 meeting of the American Association for Cancer Research, 4547.
5. Kosak KM, Saavedra JE, Keefer LK, Shami PJ (2009). A Pluronic® micelle formuation increases the stability of the novel anti-cancer nitric oxide prodrug JS-K [Abstract]. Proceedings of the 2009 meeting of the American Association for Cancer Research, 643.

Patent

1. Kosak KM, Shami PJ (2008). In Vivo Use of Glutathione S-Transferase Activated Nitric Oxide Donors. U.S. Patent No. US patent 61/034,617.. Washington, D.C.:U.S. Patent and Trademark Office.
2. Shami PJ (2002). In Vivo Use of Glutathione S-Transferase Activated Nitric Oxide Donors. U.S. Patent No. 8/404,665. Washington, D.C.:U.S. Patent and Trademark Office.

Huntsman Cancer Institute News

• Partnership Advances Targeted Therapies for Blood Cancers